Top Markets
#1 Nesa Nesa +801.14%
#2 Cortex Cortex +68.31%
#3 Wrapped Aave Ethereum USDT Wrapped Aave Ethereum USDT +66.37%
#4 Merlin's Seal BTC Merlin's Seal BTC +45.38%
#5 Pons Pons +24.75%
#6 QuantixAI QuantixAI +23.71%
#7 EXOD EXOD +22.78%
#8 Instadapp Instadapp +18.46%
#9 Movement Movement +12.71%
#10 SkyAI SkyAI +11.87%
Coin of the day
Nesa Nesa
설정
언어
한국어
통화
USD
테마
Oruka Therapeutics, Inc. Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc.

ORKA
주식 순위 #3147
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
주가
$100.91
마지막 동기화: 2026-08-25
시가총액
$6.09B
변동 (1일)
-1.47%
변동 (1년)
581.36%
국가
US
거래 Oruka Therapeutics, Inc. (ORKA)

카테고리

Healthcare
Oruka Therapeutics, Inc. (ORKA)의 EPS
2026 기준 EPS TTM: 0
Oruka Therapeutics, Inc.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 0입니다. 2026년 말에는 회사의 EPS가 0였으며, 이는 2026년의 EPS 0와 동일입니다.
Oruka Therapeutics, Inc.의 EPS 기록 (2026 ~ 2026)
매년 말의 EPS
연도 EPS 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 EPS
회사 EPS EPS 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $-7.98 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $-5.29 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH